Editas Medicine, Inc. (NASDAQ:EDIT) shares, dropped in value on Wednesday, Jan 13, with the stock price down by -2.27% to the previous day’s close as weak demand from buyers trailed the stock to $73.3.
Actively observing the price movement in the last trading, the stock closed the session at $75, falling within a range of $72.69 and $76.95. The value of beta (5-year monthly) was 2.1 whereas the PE ratio was 0 over 12-month period. Referring to stock’s 52-week performance, its high was $99.95, and the low was $14.01. On the whole, EDIT has fluctuated by 18.38% over the past month.
With the market capitalization of Editas Medicine, Inc. currently standing at about $4.52 Billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 24, 2021- Mar 01, 2021. The company’s Forward Dividend Ratio is 0, with its dividend yield at 0%. As a result, investors may see a weakening in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.75, which is expected to increase to -$2.68 for fiscal year 2021 and then to about -$3.32 by fiscal year 2022. Data indicates that the EPS growth is expected to be -0.36% in 2021, while the next year’s EPS growth is forecast to be 0.94%.
Analysts have estimated the company’s revenue for the quarter at $6.27 Million, with a low estimate of $2Million and a high estimate of $10.7 Million. According to the average forecast, sales growth in current quarter could fell down -49%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2021, the company’s y-o-y revenues would reach $85.02 Million, representing an increase of 314.1% from the revenues reported in the last year’s results.
We see that EDIT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
11 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 5 analyst(s), 5 recommend it as a Buy and no body called the EDIT stock Outperform. In the meantime, 1 analyst(s) believe the stock as Underperform and none think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of EDIT currently trading nearly -3.19% and 44.96% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.1, while the 7-day volatility ratio is showing 12.08% which for the 30-day chart, stands at 12.91%. Furthermore, Editas Medicine, Inc. (EDIT)’s beta value is 2.1, and its average true range (ATR) is 9.09. The company’s stock has been forecasted to trade at an average price of $48.57 over the course of the next 52 weeks, with a low of $14 and a high of $86. Based on these price targets, the low is -80.9 off current price, whereas the price has to move +17.33% to reach the yearly target high. Additionally, analysts’ median price of $46 is likely to be welcomed by investors because it represents an increase of -37.24% from the current levels.
A comparison of Editas Medicine, Inc. (EDIT) with its peers suggests the former has fared considerably weaker in the market. EDIT showed an intraday change of -2.27% in last session, and over the past year, it grew by +125.47%. In comparison, Bristol-Myers Squibb Company (BMY) has moved lower at -1.07% on the day and was down -2.57% over the past 12 months. On the other hand, the price of Amgen Inc (AMGN) has risen 0.49% on the day. The stock, however, is off -0.94% from where it was a year ago. Additionally, there is a decline of -227% for Gilead Sciences Inc (GILD) in last trading while the stock has seen an overall apprecation of 125.47% over the past year. The PE ratio stands at 0 for Editas Medicine, Inc., compared to 0 for Bristol-Myers Squibb Company, and 19.17 for Amgen Inc. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.23%. Meanwhile, the Dow Jones Industrial weakened by -0.03%.
Data on historical trading for Editas Medicine, Inc. (NASDAQ:EDIT) indicates that the trading volumes over the past 10 days have averaged 2.98 Million and over the past 3 months, they’ve averaged 2.07 Million. According to company’s latest data on outstanding shares, there are 62.99 Million shares outstanding.
Nearly 1.37% of Editas Medicine, Inc.’s shares belong to company insiders and institutional investors own 82.21% of the company’s shares, according to Thomson Reuters’ data. The data on short interest also indicates that stock shorts accounted for 9.89 Million shares as on December 30, 2020, resulting in a short ratio of 2.79. According to the data, the short interest in Editas Medicine, Inc. (EDIT) stood at 15.78% of shares outstanding as of December 30, 2020; the number of short shares registered in November reached 11.06 Million. The stock has risen by +4.55% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EDIT stock heading into the next quarter.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.